Four things to know about our acquisition of Valencia Technologies

Boston Scientific announced the acquisition of Valencia Technologies, the developer of the eCoin System, a minimally invasive tibial neurostimulation therapy designed to treat urge urinary incontinence, a common symptom of overactive bladder. The eCoin System offers an alternative to existing therapies by stimulating the tibial nerve near the ankle, providing a low-maintenance option for patients who may not qualify for or prefer other treatments. Kristin LaRocca, general manager of Prosthetic Urology and Pelvic Health at Boston Scientific, highlighted the company’s goal to increase patient therapy awareness and access to care through expanded treatment options.

Overactive bladder affects nearly 30 million adults in the U.S. aged 40 and older, yet only a small percentage receive treatment due to barriers such as uncertainty about symptoms or perceived normalcy of aging. The eCoin System, an implantable therapy, is designed to be a practical solution with a minimally invasive procedure typically completed in about 20 minutes, offering a potential alternative to therapies requiring frequent interventions like Botox injections every six to 12 months.

By adding the eCoin System to its portfolio alongside therapies like Axonics Sacral Neuromodulation, Boston Scientific aims to provide physicians and patients with more choices to determine the most suitable treatment path. The eCoin System stimulates the tibial nerve, differing from sacral neuromodulation, which targets nerves near the lower back, catering to patient preferences and symptom severity.

Boston Scientific emphasized its commitment to growing its incontinence treatment portfolio through strategic acquisitions and internal development, now offering one of the broadest options in the space. The company expressed optimism about expanding access to care for an underserved patient population, aiming to meet individuals at different stages of their treatment journey.